|
| [1]DEB-PAC治疗去势抵抗性前列腺癌的前瞻性随机对照研究 |
| A prospective randomized controlled study of DEB-PAC in the treatment of castration-resistant prostate cancer |
| 投稿时间：2024-07-18 修订日期：2024-08-05 |
| DOI： |
|
 |
| 中文关键词: 去势抵抗性前列腺癌 超选择性前列腺动脉化疗栓塞 多西他赛 博来霉素 前瞻性随机对照 |
| 英文关键词:Castration-Resistant Prostate Cancer Superselective Prostatic Artery Chemoembolization Docetaxel Bleomycin Prospective Randomized Controlled Trial |
| 基金项目: |
|
| 摘要点击次数: 65 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的:分析多西他赛联合博莱霉素DEB-PAC技术治疗去势抵抗性前列腺癌(CRPC)的效果。方法:采用前瞻性随机对照方法,将符合入组条件的CRPC患者64例随机分为试验组(负载多西他赛及博来霉素的药物微球前列腺动脉化疗栓塞)及对照组(全身标准多西他赛化疗方案)。治疗后对患者进行为期半年的随访观察,观察指标包括:前列腺MRI扫描观察肿瘤病灶变化情况并计算客观缓解率,治疗前后总PSA水平及血清睾酮水平缓解情况,新发全身骨转移数目、ECOG评分,以及记录不良反应发生情况。结果:治疗后,试验组与对照组客观缓解率对比,试验组更高(P<0.05)；两组患者PSA、睾酮水平,治疗后试验组PSA、睾酮水平更低(P<0.05)；两组患者ECOG评分及新发转移性病灶相比,试验组ECOG评分更低,新发转移灶更少(P<0.05)；组间不良反应发生率相比,试验组不良反应发生率更低(P<0.05)。结论:对于去势抵抗性前列腺癌患者接受DEB-PAC技术治疗获得了较好的近期临床疗效,同时减少了化疗相关不良反应的发生。 |
| 英文摘要: |
| Objective: To analyze the efficacy of DEB-PAC (Drug-Eluting Bead Prostatic Artery Chemoembolization) using a combination of docetaxel and bleomycin for the treatment of castration-resistant prostate cancer (CRPC). Methods: A prospective randomized controlled trial was conducted, enrolling 64 eligible CRPC patients. The patients were randomly assigned to either the experimental group (receiving DEB-PAC with docetaxel and bleomycin-loaded drug-eluting beads) or the control group (receiving standard systemic docetaxel chemotherapy). Patients were followed up for six months post-treatment. The primary outcome measures included changes in tumor lesions assessed via prostate MRI and calculation of the objective response rate, changes in total prostate-specific antigen (PSA) levels and serum testosterone levels before and after treatment, the number of new systemic bone metastases, ECOG performance status scores, and the incidence of adverse reactions. Results: Post-treatment, the experimental group demonstrated a higher objective response rate compared to the control group (P<0.05). The experimental group also showed significantly lower levels of PSA and testosterone after treatment compared to the control group (P<0.05). Furthermore, the experimental group exhibited lower ECOG scores and fewer new metastatic lesions (P<0.05). The incidence of adverse reactions was also significantly lower in the experimental group (P<0.05). Conclusion: DEB-PAC treatment for castration-resistant prostate cancer achieved better short-term clinical outcomes and reduced the incidence of chemotherapy-related adverse reactions. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |
|
|
|